Malignant neoplasm of uterus, part unspecified. C55 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM C55 became effective on October 1, 2018.
C55 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C55 became effective on October 1, 2021. This is the American ICD-10-CM version of C55 - other international versions of ICD-10 C55 may differ. ICD-10-CM Coding Rules C55 is applicable to female patients.
Oct 01, 2021 · Clinical Information. Primary or metastatic malignant neoplasm involving the endometrium (mucous membrane that lines the endometrial cavity). ICD-10-CM C54.1 is grouped within Diagnostic Related Group (s) (MS-DRG v39.0): 736 Uterine and adnexa procedures for ovarian or adnexal malignancy with mcc.
Oct 01, 2021 · C79.82 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C79.82 became effective on October 1, 2021. This is the American ICD-10-CM version of C79.82 - other international versions of ICD-10 C79.82 may differ.
Hyperplasia (adenomatous) (cystic) (glandular) of endometrium. Hyperplastic endometritis. ICD-10-CM Diagnosis Code D07.0 [convert to ICD-9-CM] Carcinoma in situ of endometrium. Cancer in situ of uterus; Cancer in situ, endometrium; Carcinoma in …
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
Approximate Synonyms. Adenocarcinoma of endometrium. Cancer of the endometrium. Cancer of the endometrium, adenocarcinoma. Cancer of the endometrium, adenosquamous. Cancer of the endometrium, clear cell. Cancer of the endometrium, mixed mullerian. Cancer of the endometrium, papillary serous.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...
Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix. The uterus, or womb, is an important female reproductive organ. It is the place where a baby grows when a women is pregnant. There are different types of uterine cancer. The most common type starts in the endometrium, the lining of the uterus.
Cancer that forms in tissues of the uterus (the small, hollow, pear-shaped organ in a woman's pelvis in which a fetus develops). Two types of uterine cancer are endometrial cancer (cancer that begins in cells lining the uterus) and uterine sarcoma (a rare cancer that begins in muscle or other tissues in the uterus).
Two types of uterine cancer are endometrial cancer (cancer that begins in cells lining the uterus) and uterine sarcoma (a rare cancer that begins in muscle or other tissues in the uterus). Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only , the secondary neoplasm is designated as the principal diagnosis even though the primary malignancy is still present .
The malignancy for which the therapy is being administered should be assigned as a secondary diagnosis. If a patient admission/encounter is for the insertion or implantation of radioactive elements (e.g., brachytherapy) the appropriate code for the malignancy is sequenced as the principal or first-listed diagnosis.
Symptoms, signs, and ill-defined conditions listed in Chapter 18 characteristic of, or associated with, an existing primary or secondary site malignancy cannot be used to replace the malignancy as principal or first-listed diagnosis, regardless of the number of admissions or encounters for treatment and care of the neoplasm.
When a primary malignancy has been excised but further treatment, such as an additional surgery for the malignancy, radiation therapy or chemotherapy is directed to that site, the primary malignancy code should be used until treatment is completed.
If the documentation states the cancer is a metastatic cancer, but does not state the site of the metastasis, the coder will assign a code for the primary cancer, followed by code C79.9 secondary malignant neoplasm of unspecified site.
When a current cancer is no longer receiving treatment of any kind, it is coded as a history code. For instance, the patient had breast cancer (C50.xx) and underwent a mastectomy, followed by chemoradiation. The provider documents that the patient has no evidence of disease (NED).
For instance, a patient who has primary breast cancer (C50.xx) who is now seen for metastatic bone cancer will have a code for the secondary bone cancer (C79.51) sequenced before a code for the primary breast cancer (C50.xx). When a current cancer is no longer receiving treatment of any kind, it is coded as a history code.